Hepatitis B in India: Diagnosis, Treatment, and When to Start Antivirals

India’s Hepatitis B Burden: The Scale of the Problem

India has an estimated 40–50 million chronic Hepatitis B virus (HBV) carriers — the second-largest burden in the world after China. Despite an effective vaccine available since the 1980s and a national immunisation programme since 2002, millions remain infected, most without knowing it. Hepatitis B is the leading cause of cirrhosis and hepatocellular carcinoma (liver cancer) in India.

How Is Hepatitis B Transmitted?

• Vertical (mother-to-child) — the dominant route in India; most chronic infections are acquired at birth from an infected mother. A mother with high viral load (HBV DNA >200,000 IU/mL) has a >90% chance of transmitting to the newborn without intervention.
• Horizontal (household) — shared razors, toothbrushes, nail cutters; minor cuts and skin breaks allow spread within families
• Sexual transmission — unprotected sex with an infected partner
• Iatrogenic — unsterilised needles, blood transfusions before mandatory HBsAg screening, tattooing and piercing with shared equipment

Who Should Be Tested for Hepatitis B?

APASL and EASL guidelines recommend testing in:

• All first-degree relatives (parents, siblings, children) of known HBsAg-positive individuals
• Sexual partners of HBsAg-positive individuals
• Pregnant women (universal antenatal screening)
• Healthcare workers
• People born in India or from Indian-origin families who were not vaccinated
• Anyone with elevated liver enzymes (ALT/AST) without a clear cause

The Key Blood Tests Explained

• HBsAg — the surface antigen; positive = infected with HBV (acute or chronic)
• Anti-HBs (HBsAb) — protective antibody; positive after vaccination or resolved infection
• HBeAg / Anti-HBe — markers of active viral replication; HBeAg-positive means high replication
• HBV DNA (viral load) — quantifies the virus; essential for treatment decisions
• HBV genotype — determines likely natural history and response to interferon; Genotypes A, B, C, D predominate in India
• LFTs, platelet count, FibroScan — assess degree of liver damage

When Does Hepatitis B Need Treatment?

Not every HBsAg-positive person requires immediate antiviral therapy. The decision is based on viral load, liver inflammation (ALT), and degree of fibrosis. Per APASL 2023 guidelines:

• Treat if HBV DNA >2,000 IU/mL with ALT elevation or significant fibrosis (≥F2 on FibroScan or biopsy)
• Treat regardless of viral load if cirrhosis is present
• Consider treatment if age >30 with persistent HBV DNA >2,000 IU/mL even with normal ALT
• Treat before immunosuppression, chemotherapy, or biological therapy to prevent HBV reactivation

What Are the Treatment Options?

• Tenofovir disoproxil fumarate (TDF) — first-line in India; potent, low resistance, affordable as generic. A cost-effective option for the public health setting.
• Tenofovir alafenamide (TAF) — safer renal and bone profile than TDF; preferred in patients with renal impairment or osteoporosis
• Entecavir (ETV) — alternative first-line; avoid in lamivudine-experienced patients due to cross-resistance
• Pegylated interferon-alpha — finite duration (48 weeks); aim for HBsAg loss; suitable for HBeAg-positive, young patients with Genotype A/B, elevated ALT, and no cirrhosis. Not for everyone.

Current antivirals suppress HBV but rarely cure it (HBsAg loss rate ~1%/year). Research towards a functional cure — drugs targeting cccDNA and capsid assembly modulators — is active. This is unlikely to be available widely in India before 2027–2028.

Hepatitis B Vaccination: Who and When?

• Birth dose — within 24 hours of birth; most critical dose for preventing mother-to-child transmission
• Standard schedule — 0, 1, 6 months (3 doses); produces protective anti-HBs in >95% of healthy adults
• Catch-up vaccination — all unvaccinated adults, especially healthcare workers, family contacts of HBsAg-positive individuals
• Check anti-HBs titre — one month after completing the series; >10 mIU/mL = protected
• Non-responders — repeat 3-dose series; if still non-responsive, consider double-dose schedule

Preventing Reactivation in Immunosuppressed Patients

HBV reactivation is a potentially fatal complication when patients with chronic HBV (or resolved HBV with detectable anti-HBc) receive chemotherapy, biologicals (rituximab, TNF-alpha inhibitors), corticosteroids, or transplant immunosuppression. Every patient starting immunosuppression must be screened for HBsAg and anti-HBc before therapy begins. Prophylactic antiviral (TDF or ETV) must be started before immunosuppression and continued for 6–12 months after it ends.

Frequently Asked Questions

Can Hepatitis B be cured?

Current antivirals suppress the virus effectively and prevent liver disease progression, but do not cure HBV in most cases. Functional cure (HBsAg loss) occurs in fewer than 5% of patients on long-term antivirals. Research into cccDNA-targeting agents is ongoing. For now, suppression with TDF or ETV is a lifelong but highly effective strategy.

Is Hepatitis B treatment available in Mumbai?

Yes. Generic TDF and ETV are widely available in India at low cost. Specialist monitoring — viral load, LFTs, FibroScan — is essential every 6–12 months to track response and detect fibrosis progression. Dr. Chetan Kalal at Gleneagles Hospital Mumbai provides complete Hepatitis B management including antiviral initiation, monitoring, and liver cancer surveillance.

What is the best hepatitis B specialist in Mumbai?

Dr. Chetan Kalal — DM Hepatology (ILBS), Associate Director at Gleneagles Hospital Mumbai — manages Hepatitis B comprehensively: initial workup, antiviral therapy selection, resistance testing, HCC surveillance, and management of cirrhosis complications. He follows APASL and EASL guidelines.